[{"orgOrder":0,"company":"Biorasi","sponsor":"Therapeutic Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell\u2122 Universal Donor Stem Cell Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Biorasi","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Biorasi","sponsor":"Longeveron","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B\u2122 for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Biorasi","sponsor":"Alzamend Neuro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I\/IIA Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Biorasi
ALZN002 is a proprietary active immunotherapy product. It consists of autologous DCs, which are activated WBCs taken from each individual patient that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.
Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of adult donors. Longeveron is advancing Lomecel-B through clinical trials in 3 indications: Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and Aging Frailty.
Lead Product(s):
Allogeneic Bone Marrow-derived Medicinal Signaling Cells
Mino-Lok (minocycline) is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs).
JadiCell (mesenchymal stem cells), was shown to be 100% effective in saving the lives of COVID-19 patients under age of 85 in a double-blind, randomized, placebo controlled clinical trial with patients in the ICU on a ventilator.